BioArctic AB (publ)

BATS-CHIXE:BIOABS Stock Report

Market Cap: SEK 29.3b

BioArctic Valuation

Is BIOABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of BIOABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BIOABS (SEK328.7) is trading above our estimate of future cash flow value (SEK290.91)

Significantly Below Future Cash Flow Value: BIOABS is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOABS?

Key metric: As BIOABS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIOABS. This is calculated by dividing BIOABS's market cap by their current earnings.
What is BIOABS's PE Ratio?
PE Ratio137.5x
EarningsSEK 213.24m
Market CapSEK 29.33b

Price to Earnings Ratio vs Peers

How does BIOABS's PE Ratio compare to its peers?

The above table shows the PE ratio for BIOABS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20x
GNS Genus
32.3x-2.50%UK£1.5b
BVXP Bioventix
11.2xn/aUK£83.6m
AREC Arecor Therapeutics
25.7xn/aUK£24.0m
HIK Hikma Pharmaceuticals
11x8.69%UK£3.3b
BIOABS BioArctic
137.5x53.32%SEK 29.3b

Price-To-Earnings vs Peers: BIOABS is expensive based on its Price-To-Earnings Ratio (137.5x) compared to the peer average (20x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BIOABS's PE Ratio compare vs other companies in the European Biotechs Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies8PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIOABS is expensive based on its Price-To-Earnings Ratio (137.5x) compared to the European Biotechs industry average (17x).

Price to Earnings Ratio vs Fair Ratio

What is BIOABS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOABS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio137.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIOABS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIOABS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 328.70
SEK 301.40
-8.31%
14.62%SEK 363.00SEK 240.00n/a5
Jun ’27n/a
SEK 301.40
0%
14.62%SEK 363.00SEK 240.00n/a5
May ’27SEK 317.60
SEK 301.40
-5.10%
13.98%SEK 355.00SEK 240.00n/a5
Apr ’27SEK 329.20
SEK 303.80
-7.72%
14.93%SEK 367.00SEK 240.00n/a5
Mar ’27n/a
SEK 303.80
0%
14.93%SEK 367.00SEK 240.00n/a5
Feb ’27SEK 332.80
SEK 295.60
-11.18%
13.45%SEK 339.00SEK 230.00n/a5
Jan ’27SEK 311.40
SEK 295.60
-5.07%
13.45%SEK 339.00SEK 230.00n/a5
Dec ’26n/a
SEK 295.60
0%
13.45%SEK 339.00SEK 230.00n/a5
Nov ’26n/a
SEK 294.80
0%
15.64%SEK 355.00SEK 220.00n/a5
Oct ’26SEK 284.90
SEK 294.60
+3.40%
15.53%SEK 353.00SEK 220.00n/a5
Sep ’26SEK 312.50
SEK 280.50
-10.24%
12.35%SEK 330.00SEK 232.00n/a4
Aug ’26SEK 207.00
SEK 284.50
+37.44%
15.24%SEK 350.00SEK 228.00n/a4
Jul ’26SEK 177.35
SEK 286.75
+61.69%
14.13%SEK 350.00SEK 237.00SEK 328.704
Jun ’26SEK 177.10
SEK 296.40
+67.36%
12.65%SEK 350.00SEK 237.00n/a5
May ’26n/a
SEK 314.40
0%
11.71%SEK 360.00SEK 267.00SEK 317.605
Apr ’26n/a
SEK 334.60
0%
5.98%SEK 360.00SEK 308.00SEK 329.205
Mar ’26n/a
SEK 332.60
0%
5.34%SEK 350.00SEK 308.00n/a5
Feb ’26n/a
SEK 326.80
0%
4.72%SEK 350.00SEK 310.00SEK 332.805
Jan ’26n/a
SEK 322.00
0%
6.47%SEK 350.00SEK 292.00SEK 311.405
Dec ’25SEK 195.40
SEK 322.00
+64.79%
6.47%SEK 350.00SEK 292.00n/a5
Nov ’25n/a
SEK 292.20
0%
8.54%SEK 340.00SEK 270.00n/a5
Oct ’25SEK 158.45
SEK 290.60
+83.40%
8.80%SEK 340.00SEK 270.00SEK 284.905
Sep ’25n/a
SEK 290.60
0%
8.80%SEK 340.00SEK 270.00SEK 312.505
Aug ’25n/a
SEK 336.40
0%
8.10%SEK 370.00SEK 290.00SEK 207.005
Jul ’25n/a
SEK 368.00
0%
11.80%SEK 450.00SEK 325.00SEK 177.355
SEK 299.67
Fair Value
9.7% overvalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 07:30
End of Day Share Price 2026/06/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioArctic AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonDNB Carnegie
Rajan SharmaGoldman Sachs
Viktor SundbergNordea Markets